-
Mashup Score: 3
Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, introduces a genomic classification system that can be used alongside measurable residual disease (MRD) to guide transplant decision-making for patients with acute myeloid leukemia (AML). Dr Versluis recommends that patients with favorable-risk cytogenetics do not always require transplantation, especially those who are MRD-negative. Transplantation should be considered for patients with adverse-risk cytogenetics or patients who remain MRD-positive after induction treatment. For patients with intermediate-risk cytogenetics, MRD levels should be used to guide transplant decisions. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0ESH MDS 2024 | VJHemOnc - 21 hour(s) ago
The 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) took place on April 12-14, 2024, in Budapest, Hungary. This event brought together experts from around the world to discuss the diagnosis and treatment of myelodysplastic syndromes. The 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) took place on April 12-14, 2024, in Budapest, Hungary. This event brought together experts from around the world to discuss the diagnosis and treatment of myelodysplas
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Robin FoΓ , MD, Sapienza University of Rome, Rome, Italy, discusses whether transplantation and chemotherapy are necessary for all patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL), given advancements in immunotherapy and tyrosine kinase inhibitors (TKIs). The GIMEMA LAL2116 (D-ALBA) study (NCT02744768) found favorable long-term survival in patients treated with dasatinib plus steroids and consolidated with blinatumomab, with transplantation only necessary for those who were measurable residual disease (MRD)-positive. The ongoing GIMEMA ALL2820 trial (NCT04722848) is comparing ponatinib and blinatumomab vs chemotherapy and imatinib in Ph+ ALL, aiming to define which patients require chemotherapy. This trial emphasizes CNS prophylaxis due to some CNS localization observed in the D-ALBA study. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copy
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Cytogenetic and molecular associations with outcomes in HR-MDS treated with HMAs plus venetoclax - 2 day(s) ago
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study exploring cytogenetic and molecular associations with outcomes in high-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMAs) plus venetoclax. As was expected, patients with a complex karyotype and TP53 mutation exhibited a lower response rate and duration of response. However, Prof. Garcia-Manero emphasizes that the data does not mean that HMA plus venetoclax combinations should not be used in poor-risk patients, as responses were superior to HMA alone and may allow these patients to be bridged to transplant. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 31
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context of recurrent genetic alterations.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 24Looking forward to COMy 2024: celebrating 10 years - 3 day(s) ago
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement for the upcoming 10th World Congress on Controversies in Multiple Myeloma (COMy), which is being held in Paris, France, on May 23-26, 2024. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 212Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers - 3 day(s) ago
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM) who are treated with CAR-T cells and T-cell engagers. Dr Paiva notes that the role of MRD in the era of newer immunotherapies is uncertain. Data from an analysis of patients showed that, although achieving MRD negativity was the most relevant prognostic factor, it may not hold the same significance as a clinical endpoint that it does with other treatment options. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
@BrunoPaiva_UNA on the clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagersπ©Έπ₯ π https://t.co/jrMammvREg Interested in #MRD in #Myeloma? Join us for the Miami Myeloma MRD 2024 Virtual Workshop π£ Register π https://t.co/xbG1G1O4xT https://t.co/G4nAh3LskO
-
-
Mashup Score: 212Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers - 3 day(s) ago
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM) who are treated with CAR-T cells and T-cell engagers. Dr Paiva notes that the role of MRD in the era of newer immunotherapies is uncertain. Data from an analysis of patients showed that, although achieving MRD negativity was the most relevant prognostic factor, it may not hold the same significance as a clinical endpoint that it does with other treatment options. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
@BrunoPaiva_UNA on the clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagersπ©Έπ₯ π https://t.co/jrMammvREg Interested in #MRD in #Myeloma? Join us for the Miami Myeloma MRD 2024 Virtual Workshop π£ Register π https://t.co/xbG1G1O4xT https://t.co/G4nAh3LskO
-
-
Mashup Score: 11PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT - 4 day(s) ago
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, introduces the PHOEBUS study (NCT05762211), a Phase IIb trial investigating the use of MaaT003, an oral pooled fecal microbiotherapy, in patients with hematological malignancies undergoing allogeneic stem cell transplantation (alloSCT). Dr Malard outlines the study design and hopes that this novel therapeutic approach will increase the overall survival (OS) of patients by preventing transplant-related complications. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Personalized risk assessment for transplantation in primary immunodeficiency disorders - 4 day(s) ago
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses an individualized approach to assessing potential risks of bone marrow transplantation in the treatment of primary immunodeficiency disorders (or inborn errors of immunity). The combination of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT CI) and the Immune Deficiency and Dysregulation Activity (IDDA) score allows for the individualization of transplant risk to guide treatment decisions. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
#EBMT24 | @JurjenVersluis (@ErasmusMC) discusses the integration of genomics and MRD into transplant decision-making for patients with AML. Click here to watch the exclusive interview: π https://t.co/HD5XDRmUho #HemOnc #AMLsm #Leusm #BMTsm @TheEBMT